Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZD6474 · 16 trials · 18 indications
Median time to progression (months) from randomisation until objective disease progression (determined by RECIST assessments) or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Values here are estimated (from a Weibull model) as the medians were not met.
Overall Survival (OS) is defined as the time from date of randomization until death. Any blinded/unknown patient which have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie, their status must be known at the censored date and should not be lost to follow up or unknown).
To assess the effect of vandetanib on biological progression free rate based on PSA level (assessable set). PSA progression free rate defined as the number of participants with : * After decline from baseline: a 25% increase above the nadir * No decline from baseline: a 25% increase above the baseline (min. increase of 2 ng/mL)
The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria. The categories for best objective response are CR, PR, stable disease (SD)\>= 12 weeks, progressive disease (PD) or NE.
The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) defined according to RECIST 1.0.
| Arm | Type | Description |
|---|---|---|
| 1 | NO_INTERVENTION | Placebo vandetanib |
| 2 | EXPERIMENTAL | Vandetanib |
| ZD6474 100mg | EXPERIMENTAL | Daily dose |
| ZD6474 200mg | EXPERIMENTAL | daily dose |
| ZD6474 300mg | EXPERIMENTAL | daily dose |
| Caprelsa (vandetanib) 300 mg | EXPERIMENTAL | Daily oral dose of Caprelsa (vandetanib) 300mg |
| ZD6474 (vandetanib) 100mg | EXPERIMENTAL | - |
| ZD6474 (vandetanib) 300mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ZD6474 (Vandetanib) | DRUG | once daily oral tablet |
| Best Supportive Care | OTHER | standard of care |
| Bicalutamide | DRUG | 150mg orally, once daily |
| Placebo | DRUG | orally, once daily |
| ZD6474 (vandetanib) 100mg | DRUG | once daily oral dose |
| ZD6474 (vandetanib) 200mg | DRUG | once daily oral dose |
| ZD6474 (vandetanib) 300mg | DRUG | once daily oral dose |
| ZD6474 | DRUG | - |
| Paclitaxel | DRUG | - |
| Carboplatin | DRUG | - |
| ZD1839 | DRUG | - |
| VEGF-receptor tyrosine kinase (KDR) | DRUG | - |
| Docetaxel | DRUG | - |
| Cisplatin | DRUG | intravenous infusion |
| Radiation | RADIATION | radiation of head and neck |
| ZD6474 (Zactima) 100mg | DRUG | - |
| Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR) | PROCEDURE | - |
| Biomarker Draws | PROCEDURE | - |
| ZD6474 (Zactima) 300mg | DRUG | - |
| 5-Fluorouracil | DRUG | intravenous infusion |
| Leucovorin | DRUG | intravenous infusion |
| Oxaliplatin | DRUG | intravenous infusion |
| Irinotecan | DRUG | intravenous infusion |
| pemetrexed | DRUG | intravenous infusion |
Inclusion Criteria: * Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer. * Presence of measurable tumor * Able to swallow medication Exclusion Criteria: * Major surgery within 4 weeks before randomization * Last dose of prior chemo...
ZD6474 is an investigational small molecule being studied for the treatment of several cancers, including non-small cell lung cancer, prostate cancer, and advanced colorectal carcinoma. It has been evaluated in clinical trials for these oncology indications, though it remains in clinical development and is not approved.
ZD6474 is a small molecule that targets vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) pathways. By inhibiting these receptors, it aims to block tumor angiogenesis and cancer cell growth, which is relevant to its study in solid tumors like non-small cell lung cancer.
ZD6474 is being developed by Sanofi, a global pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi has sponsored clinical trials of ZD6474 in oncology indications, including non-small cell lung cancer and prostate cancer.
ZD6474 is in Phase 1 of clinical development, though completed trials have been conducted at Phase 2. It is an investigational drug, meaning it has not received FDA approval and is still being studied for safety and efficacy in cancer patients.
ZD6474 has been studied in several completed clinical trials, including NCT00059722, which compared ZD6474 with ZD1839 in non-small cell lung cancer, and NCT00252746, a Phase IIa dose-finding study in non-small cell lung carcinoma. Other trials include NCT00071188 and NCT00659438.
Yes, ZD6474 is also known as Zactima, as referenced in a clinical trial title for patients with castration-refractory metastatic prostate cancer. This alternative name is used in some research contexts, so readers searching for Zactima will find information about ZD6474.